Postinflammatory hyperpigmentation - Iperpigmentazzjoni Postinfjammatorja
Iperpigmentazzjoni Postinfjammatorja (Postinflammatory hyperpigmentation) hija kundizzjoni tal-ġilda kkaratterizzata minn żieda fil-pigment fil-ġilda wara infjammazzjoni tal-ġilda. iperpigmentazzjoni postinfjammatorja (postinflammatory hyperpigmentation) tista' tkun ikkawżata minn espożizzjoni fit-tul għax-xemx, infjammazzjoni, jew korrimenti oħra tal-ġilda, inklużi dawk relatati mal-akne. Nies b'tonijiet tal-ġilda aktar skur huma ġeneralment aktar suxxettibbli għall-iperpigmentazzjoni b'espożizzjoni żejda għax-xemx.
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
References
Postinflammatory hyperpigmentation (PIH) hija problema tal-ġilda frekwenti li sseħħ wara infjammazzjoni jew korriment tal-ġilda. Għandha tendenza li ddum għal żmien twil u hija agħar f'nies b'tonijiet tal-ġilda aktar skur (Fitzpatrick skin types III–VI) . Għalkemm ħafna drabi titjieb waħdu, dan jista 'jieħu ftit, għalhekk it-trattament ħafna drabi jkun meħtieġ għal żmien twil. Li tgħaqqad trattamenti differenti taħdem l-aħjar.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation hija konsegwenzi komuni ta' infjammazzjoni tal-ġilda. Hija għandha t-tendenza li taffettwa individwi b'ġilda aktar skura b'mod aktar sever u ta 'spiss. Studji juru li kwistjonijiet bħal postinflammatory hyperpigmentation huma fost ir-raġunijiet ewlenin għaliex in-nies b'tonijiet tal-ġilda aktar skur ifittxu kura dermatoloġika. Trattament bikri huwa kruċjali biex tissolva postinflammatory hyperpigmentation u normalment tibda bil-ġestjoni tal-kundizzjoni infjammatorja inizjali. L-ewwel linja ta 'trattament tipikament tinvolvi l-użu ta' aġenti topiċi li jħaffu l-ġilda flimkien ma 'ħarsien mix-xemx għall-protezzjoni. Dawn l-aġenti, bħal hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , jistgħu effettivament inaqqsu pigmentazzjoni eċċessiva. Barra minn hekk, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy jintużaw ukoll bħala aġenti depigmentanti, bi trattamenti ġodda emerġenti. Filwaqt li t-trattamenti topiċi huma ġeneralment effettivi għall-iperpigmentazzjoni fil-livell tal-wiċċ, proċeduri (laser, chemical peel) jistgħu jkunu meħtieġa għal każijiet iebsa. Huwa importanti li tuża kawtela ma 'dawn it-trattamenti biex tevita irritazzjoni u aggravar ta' postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
